BACKGROUND AND PURPOSE: A subset of patients with malignant glioma develops conspicuous lesions characterized by persistent restricted diffusion during treatment with bevacizumab. The purpose of the current study was to characterize the evolution of these lesions and to determine their relationship to patient outcome. MATERIALS AND METHODS: Twenty patients with malignant glioma with persistent restricted-diffusion lesions undergoing treatment with bevacizumab were included in the current study. Mean ADC and the volume of restricted diffusion were computed for each patient during serial follow-up. Differences in TTP, TTS, and OS were compared between patients with restricted diffusion and matched controls by using Kaplan-Meier analysis with the logrank test and Cox hazard models. RESULTS: Mean ADC values were generally stable with time (mean, 5.2 ± 12.6% change from baseline). The volume of restricted diffusion increased a median of 23% from baseline by 6 months. Patients with restricted-diffusion lesions had significantly greater TTP (logrank, P = .013), TTS (logrank, P = .008), and OS (logrank, P = .010) than matched controls. When available, advanced physiologic imaging of restricted-diffusion lesions showed hypovascularity on perfusion MR imaging and decreased amino acid uptake on (18)F-FDOPA PET scans. Atypical gelatinous necrotic tissue was confirmed in the area of restricted diffusion in 1 patient. CONCLUSIONS: Restricted-diffusion lesions in malignant gliomas treated with bevacizumab are generally stable with time and are associated with improved outcomes. These results combined with physiologic imaging and histopathologic data suggest that these lesions are not consistent with aggressive tumor.
BACKGROUND AND PURPOSE: A subset of patients with malignant glioma develops conspicuous lesions characterized by persistent restricted diffusion during treatment with bevacizumab. The purpose of the current study was to characterize the evolution of these lesions and to determine their relationship to patient outcome. MATERIALS AND METHODS: Twenty patients with malignant glioma with persistent restricted-diffusion lesions undergoing treatment with bevacizumab were included in the current study. Mean ADC and the volume of restricted diffusion were computed for each patient during serial follow-up. Differences in TTP, TTS, and OS were compared between patients with restricted diffusion and matched controls by using Kaplan-Meier analysis with the logrank test and Cox hazard models. RESULTS: Mean ADC values were generally stable with time (mean, 5.2 ± 12.6% change from baseline). The volume of restricted diffusion increased a median of 23% from baseline by 6 months. Patients with restricted-diffusion lesions had significantly greater TTP (logrank, P = .013), TTS (logrank, P = .008), and OS (logrank, P = .010) than matched controls. When available, advanced physiologic imaging of restricted-diffusion lesions showed hypovascularity on perfusion MR imaging and decreased amino acid uptake on (18)F-FDOPA PET scans. Atypical gelatinous necrotic tissue was confirmed in the area of restricted diffusion in 1 patient. CONCLUSIONS: Restricted-diffusion lesions in malignant gliomas treated with bevacizumab are generally stable with time and are associated with improved outcomes. These results combined with physiologic imaging and histopathologic data suggest that these lesions are not consistent with aggressive tumor.
Authors: Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope Journal: J Neurooncol Date: 2011-03-26 Impact factor: 4.130
Authors: Benjamin M Ellingson; Mark G Malkin; Scott D Rand; Jennifer M Connelly; Carolyn Quinsey; Pete S LaViolette; Devyani P Bedekar; Kathleen M Schmainda Journal: J Magn Reson Imaging Date: 2010-03 Impact factor: 4.813
Authors: Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Paul S Mischel; Whitney B Pope Journal: Neuro Oncol Date: 2011-02-15 Impact factor: 12.300
Authors: L R Rogers; J Gutierrez; L Scarpace; L Schultz; S Ryu; B Lord; B Movsas; J Honsowetz; R Jain Journal: J Neurooncol Date: 2010-05-20 Impact factor: 4.130
Authors: N Sadeghi; N D'Haene; C Decaestecker; M Levivier; T Metens; C Maris; D Wikler; D Baleriaux; I Salmon; S Goldman Journal: AJNR Am J Neuroradiol Date: 2007-12-13 Impact factor: 3.825
Authors: Johannes Rieger; Oliver Bähr; Klaus Müller; Kea Franz; Joachim Steinbach; Elke Hattingen Journal: J Neurooncol Date: 2009-12-25 Impact factor: 4.130
Authors: John R Hesselink; Matthew J Barkovich; Tyler M Seibert; Nikdokht Farid; Karra A Muller; Kevin T Murphy; Santosh Kesari Journal: CNS Oncol Date: 2014
Authors: H S Nguyen; N Milbach; S L Hurrell; E Cochran; J Connelly; J A Bovi; C J Schultz; W M Mueller; S D Rand; K M Schmainda; P S LaViolette Journal: AJNR Am J Neuroradiol Date: 2016-08-04 Impact factor: 3.825
Authors: Ryan L Brunsing; Natalie M Schenker-Ahmed; Nathan S White; J Kellogg Parsons; Christopher Kane; Joshua Kuperman; Hauke Bartsch; Andrew Karim Kader; Rebecca Rakow-Penner; Tyler M Seibert; Daniel Margolis; Steven S Raman; Carrie R McDonald; Nikdokht Farid; Santosh Kesari; Donna Hansel; Ahmed Shabaik; Anders M Dale; David S Karow Journal: J Magn Reson Imaging Date: 2016-08-16 Impact factor: 4.813
Authors: Stephen F Futterer; Alexander J Nemeth; Sean A Grimm; Ann B Ragin; James P Chandler; Kenji Muro; Maryanne H Marymont; Jeffrey J Raizer Journal: J Neurooncol Date: 2014-02-28 Impact factor: 4.130
Authors: Kevin Leu; Whitney B Pope; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Wei Chen; Linda M Liau; Benjamin M Ellingson Journal: CNS Oncol Date: 2013-01